Health Canada Registry: Aspen-Semaglutide and Sevmia Approved, Neither Marketed

Last week's headlines were simple: Canada has approved a third generic Ozempic. That part is true. Aspen Pharmacare Canada announced on July 21 that Health Canada has approved Aspen-Semaglutide, a generic equivalent of Ozempic, for adults with type 2 diabetes — two pen formats (a 2 mg pen dispensing 0.25 mg or 0.5 mg doses, and a 4 mg pen dispensing 1 mg doses), and no price disclosed. The approval covers type 2 diabetes only.

Here is what the headlines did not mention: you cannot yet buy it anywhere in Canada. Rather than wait for the next press release, we went to the primary source — Health Canada's Drug Product Database, the federal government's public registry of drug products. As of July 28, 2026, both Aspen-Semaglutide DINs (02569930 and 02569949) carry a status of "Approved" and no market date.

"Approved" and "Marketed" are different columns

In the Drug Product Database, "Approved" means Health Canada has authorized a product that has not yet been put on the market. "Marketed" means the product is actually being sold in Canada, with a market date on record. The contrast is easy to see: the two generic semaglutides already sold in Canadian pharmacies — Apotex's Apo-Semaglutide and Dr Reddy's semaglutide injection — are both listed as "Marketed", with market dates in May 2026. The two newest approvals are not. Here is the registry, row by row:

Product	DIN	Status (as of July 28, 2026)	Market date
Aspen-Semaglutide, 0.25 mg / 0.5 mg pen (Aspen Pharmacare Canada)	02569930	Approved	None listed
Aspen-Semaglutide, 1 mg pen (Aspen Pharmacare Canada)	02569949	Approved	None listed
Sevmia (Apotex)	02569582	Approved	None listed
Apo-Semaglutide (Apotex)	—	Marketed	May 14, 2026
Semaglutide Injection (Dr Reddy's)	—	Marketed	May 6, 2026

Source: Health Canada Drug Product Database, checked July 28, 2026.

Sevmia: approved a month ago, same empty column

We ran the same check on the Wegovy side. Sevmia, the first generic referencing Wegovy, was approved June 29. As of July 28, Health Canada's Drug Product Database still lists it as "Approved" with no market date, and no Canadian pharmacy price has been published. Semaglutide's Canadian data exclusivity expired on January 4, 2026, which is why generic approvals are now arriving on both the Ozempic and Wegovy sides — but for the two newest entries, an approval is all there is so far.

Why approval has not become a launch

Aspen's own announcement names the bottleneck: the company says the "timing of commercialisation remains dependent on" the availability of semaglutide active pharmaceutical ingredient. That ingredient comes from Dr Reddy's — and Dr Reddy's supply picture was just quantified. Per Reuters, reporting Dr Reddy's July 22 quarterly results, the company cut its full-year semaglutide target from 12 million pens to 6–7 million and said supply will remain disrupted in Canada until at least late October, after an impurity issue in the active ingredient halted production of new batches. Reuters also reported an analyst's estimate that only about 180,000 pens had been sold globally before the halt.

Two proportions worth keeping in mind. This is a halt on future production batches, not a recall of pens already in Canada. And the pen figures are global totals, not Canada-specific numbers.

What this means for Canadian prices

Right now: nothing changes. Neither Aspen-Semaglutide nor Sevmia has a published Canadian price — Aspen disclosed none, and no pharmacy lists either product. The generic semaglutide you can actually price-shop today is Apo-Semaglutide, on Canadian pharmacy shelves since May; our Apo-Semaglutide price table tracks it by province. Telehealth services such as Felix list generic Ozempic (Apo-Semaglutide) at a flat $149 per month, all-in.

On timing: with ingredient supply disrupted until at least late October, an Aspen-Semaglutide launch before November is not realistic — so do not expect this approval to show up in Canadian prices before then. And nothing published so far says what the product will cost when it does launch. For Sevmia, there is no timing signal at all yet.

What we are watching

• A market date appearing on any of the three "Approved" DINs above — the registry signal that a product has moved from approved to marketed.
• A first Canadian pharmacy price for either product. As of July 28, none exists.
• One nuance from this week's check: Sevmia's database record was updated on July 24, but its status did not change. A record update is not a launch signal — a status change is.

Our listing watch runs daily. To hear the moment either product shows a market date or a first pharmacy price, sign up for the generic availability alert.